Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Consensus Rating of “Moderate Buy” from Analysts

Alignment Healthcare, Inc. (NASDAQ:ALHC) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $23.95.

A number of research firms have recently commented on ALHC. The Goldman Sachs Group restated a “buy” rating and set a $22.00 target price on shares of Alignment Healthcare in a research report on Monday, November 3rd. KeyCorp reissued an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a report on Thursday, January 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. UBS Group increased their target price on Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q4 results beat near‑term expectations — Alignment reported ($0.05) EPS vs. consensus (~$0.15 loss) and revenue of ~$1.01B, up ~44% year‑over‑year, showing strong top‑line growth. Alignment Healthcare Reports Fourth Quarter and Full‑Year 2025 Results
• Positive Sentiment: Company highlighted record revenue and membership gains, supporting continued Medicare Advantage enrollment momentum that underpins revenue visibility. Alignment Healthcare Inc (ALHC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst writeups and metric comparisons confirmed the beat but note persistent negative margins and ROE; these pieces provide context on profitability trends and model updates. Zacks — Key Metrics Versus Estimates
• Neutral Sentiment: Conference call / press release and filings are available for details on membership trends, medical cost assumptions and guidance drivers for 2026. Quarterly Report / Press Release PDF
• Neutral Sentiment: Reported short‑interest data in public feeds appears erroneous (zeros/NaN); no reliable short‑interest signal from those entries. Market data / profile
• Negative Sentiment: Forward guidance disappointed: Q1 revenue guidance (~$1.2B) below the ~ $1.3B street estimate and FY 2026 revenue guidance of $5.1B–$5.2B sits at or slightly under consensus — investors reacted to the softer top‑line outlook. Guidance details in Earnings Release
• Negative Sentiment: Profitability remains a concern — the company still shows a small negative net margin and negative return on equity, and management did not provide explicit EPS guidance for 2026, leaving investors uncertain on near‑term earnings conversion. Zacks — Q4 Loss, Beats Revenue Estimates

Alignment Healthcare Price Performance

NASDAQ:ALHC opened at $19.22 on Friday. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. The company has a 50 day moving average price of $20.99 and a 200-day moving average price of $18.51. Alignment Healthcare has a 1-year low of $11.63 and a 1-year high of $23.87. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of -1,920.08, a price-to-earnings-growth ratio of 5.20 and a beta of 1.16.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.10. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.53%. The firm’s revenue was up 44.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.16) earnings per share. Equities research analysts forecast that Alignment Healthcare will post -0.69 EPS for the current year.

Insiders Place Their Bets

In other news, insider Andreas P. Wagner sold 22,238 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $20.47, for a total transaction of $455,211.86. Following the completion of the sale, the insider owned 169,805 shares of the company’s stock, valued at $3,475,908.35. The trade was a 11.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Hyong Kim sold 16,506 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $21.35, for a total transaction of $352,403.10. Following the completion of the transaction, the insider directly owned 333,133 shares in the company, valued at $7,112,389.55. This represents a 4.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,125,938 shares of company stock valued at $41,799,570. 7.00% of the stock is owned by company insiders.

Institutional Trading of Alignment Healthcare

A number of institutional investors have recently made changes to their positions in the company. Allworth Financial LP increased its holdings in shares of Alignment Healthcare by 8.9% during the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock worth $137,000 after buying an additional 566 shares during the last quarter. State of Alaska Department of Revenue increased its stake in Alignment Healthcare by 6.0% during the fourth quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after acquiring an additional 636 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in Alignment Healthcare by 6.3% during the third quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after acquiring an additional 665 shares during the last quarter. Parallel Advisors LLC raised its position in Alignment Healthcare by 87.7% in the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Alignment Healthcare by 2.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock valued at $659,000 after purchasing an additional 844 shares during the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.